CoChat

Spotlight on the Fear of Cancer Recurrence Inventory (FCRI)

Open access
Smith, Allan Ben, Costa, Daniel, Galica, Jacqueline, Lebel, Sophie, Tauber, Nina, van Helmondt, Sanne Jasperine, Zachariae, Robert · 2020 · Psychology Research and Behavior Management

The DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index; 3 of the 110 sources its claims cite were checked for support.

Abstract

Fear of cancer recurrence (FCR) is a pervasive concern for people living with cancer. The rapidly expanding FCR literature has been weakened somewhat by use of miscellaneous FCR measures of varying quality. The Fear of Cancer Recurrence Inventory (FCRI) has been widely used in observational and intervention studies and the FCRI severity subscale, also known as the FCRI-Short Form (FCRI-SF), is often used to identify potential cases of clinically significant FCR. Given the FCRI's increasing use in research and clinical practice, we aimed to provide an overview, critique, and suggested improvements of the FCRI. Studies citing the original FCRI validation paper were identified and synthesised using narrative and meta-analytic methods. The 42-item FCRI has demonstrated a reasonably robust 7-factor structure across evaluations in multiple languages, although certain subscales (eg, Coping) demonstrate sub-optimal reliability. Confirmation of the cross-cultural equivalence of several FCRI translations is needed. Meta-analysis of FCRI-SF scores revealed a combined weighted mean score of 15.7/36, a little above the lowest proposed cut-off score (≥13) for clinical FCR. Depending on the FCRI-SF cut-off used, between 30.0% and 53.9% of the cancer population (ie, patients and survivors) appear to experience sub-clinical or clinical FCR. Higher FCRI scores were associated with younger age and female gender, pain/physical symptoms and psychological morbidity, consistent with the FCR literature generally. Issues regarding the application and interpretation of the FCRI remain. Whether the FCRI is well suited to assessing fear of progression as well as recurrence is unclear, the meaningfulness of the FCRI total score is debatable, and the use of the FCRI-SF to screen for clinical FCR is problematic, as items do not reflect established characteristics of clinical FCR. Refinement of the FCRI is needed for it to remain a key FCR assessment tool in future research and clinical practice.

Overview

CoChat Summary

## TL;DR

This state-of-the-art review synthesizes 198 articles citing the original FCRI validation paper and concludes that the 42-item FCRI has reasonably robust psychometric support, but some subscales and the short form have important limitations. The meta-analysis found a weighted mean FCRI-SF score of 15.7/36, with 30.0% to 53.9% of the cancer population scoring at or above proposed clinical cut-offs depending on which threshold was used.

## Key findings

  • The review identified 198 articles citing the original FCRI validation paper; 18 studies were included in the narrative synthesis of factor structure and psychometrics, and 46 studies in the meta-analysis of prevalence/severity.
  • Across 46 independent samples from 14,092 cancer patients and survivors, the aggregated weighted mean FCRI-SF score was 15.8 (95% CI: 14.5–17.1); the aggregated weighted mean FCRI-Total score was 65.2 (95% CI: 58.0–72.3).
  • Depending on the FCRI-SF cut-off, 53.9% of participants scored above ≥13, 43.3% above ≥16, and 30% above ≥22.
  • Reliability was generally good, with a weighted pooled test–retest correlation of 0.89 (95% CI: 0.80–0.98), but the Reassurance and Coping Strategies subscales were repeatedly described as less than ideal/sub-optimal.
  • Meta-regression found higher FCRI-SF scores in English-language samples (18.0; 95% CI: 16.0–20.0) than non-English samples (14.3; 95% CI: 12.9–15.7; Beta=3.7, p=0.003), and a small positive association between FCRI-SF scores and time since diagnosis (Beta=0.05, p=0.049).

## Methods

  • State-of-the-art review with three components: narrative synthesis of factor structure/psychometrics and correlates, meta-analysis of FCR prevalence and severity, and discussion of limitations/improvements.
  • Literature search used Scopus only, identifying peer-reviewed English-language articles from March 2009 to March 2020 that cited the original FCRI validation paper; all article types were eligible for the narrative review, and article quality was not assessed.
  • Meta-analytic outcomes were mean FCRI total scores, mean FCRI-SF scores, and percentages above FCRI-SF cut-offs of ≥13, ≥16, or ≥22; analyses used random effects models, with subgroup analyses/meta-regression when heterogeneity was present.

## Limitations

  • The paper states that cross-cultural equivalence has been established for only two translations, and that more work is needed to confirm equivalence across the many FCRI translations.
  • The authors note that the FCRI-SF cut-offs vary and that the short form may have low specificity and may not map well onto established characteristics of clinical FCR.
  • Evident from the text: the review searched only Scopus and included only English-language papers, and article quality was not assessed; the meta-analysis also relied heavily on samples from intervention studies, which the authors say may not represent the broader cancer population.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/prbm.s231577

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

3 Valid · 3 Not valid · 51 Not checked · 64 Own results and interpretations

56 more claims

Create a free account to see all 121 claims and to verify the 107 references still open.

See all claims — free account
  • It may state two separate claims as one. 49
  • Probably not a substantial claim. 21

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 81 references

Research works printed but not linked: 2

  1. Bateni, Arch Breast Cancer, 6, 174, 10.19187/abc.201964174-180 · doi:10.19187/abc.201964174-180
  2. van Helmondt, 2020, Eur J Cancer Care (Engl)

Cited by

Metadata

Authors
Smith, A. B., Costa, D., Galica, J., Lebel, S., Tauber, N., van Helmondt, S. J., & Zachariae, R.
Affiliations
  • UNSW Sydney (AU)
  • The University of Sydney (AU)
  • Queen's University (CA)
  • University of Ottawa (CA)
  • Aarhus University (DK)
Corresponding author
Smith, Allan Ben
Venue
Psychology Research and Behavior Management
Published
2020-12
Volume
Volume 13
Pages
1257-1268
ISSN
1179-1578 (ISSN-L)
OpenAlex
W3116015896
Cited by
98
References
82
Citations by year
2026: 18 · 2025: 20 · 2024: 16 · 2023: 15 · 2022: 18 · 2021: 11
FWCI
1.18
Type
journal article
Language
en
Open access
Locations
  • Psychology Research and Behavior Management (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
Cancer Institute NSW
Topics
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Childhood Cancer Survivors' Quality of Life
  • Social Sciences › Decision Sciences › Management Science and Operations Research › Psychometric Methodologies and Testing
Keywords
fear of cancer recurrence, psychometric properties, factor structure, reliability statistics, cross-cultural equivalence, cancer survivors, fear of progression, psychological morbidity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.